Viveve Medical (NSDQ:VIVE) filed an SEC Form D yesterday to confirm the sale of more than $3.2 million in options, warrants and other rights to acquire other securities. The company made the first sale in the offering on April 20 and has now sold the total offering amount of $3,225,875. There is a sales commission worth […]
Cutera, Senseonics and more receive Paycheck Protection Program loans
A number of medtech companies announced that they received millions of dollars in loans through the Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security (CARES) Act. Cutera (NSDQ:CUTR), Senseonics (NYSE:SENS), Viveve Medical (NSDQ:VIVE) and Encision (ECIA:ECIA) received approximately $15 million combined through the program administered by the U.S. Small Business Administration amid the COVID-19 pandemic. […]
Viveve looking at ‘stategic alternatives’ after trial misses the mark
Viveve Medical (NSDQ:VIVE) announced today that the clinical trial for its cryogen-cooled monopolar radiofrequency (CMRF) technology did not meet its primary endpoint. The company added that it is currently evaluating strategic alternatives and assessing its organization and cost structure following the missed endpoint amid the current COVID-19 pandemic. The Viveve II clinical trial is a multicenter, […]
Viveve Medical completes enrollment for study of its stress urinary incontinence treatment
Viveve Medical (NSDQ:VIVE) announced that it completed enrollment in a short-term feasibility study for its cryogen-cooled monopolar radiofrequency (CMRF) treatment for stress urinary incontinence (SUI) in women. The international, three-arm study is a prospective, randomized, single-blind clinical trial comparing Viveve’s CMRF treatment and a cryogen-only sham to an inert sham treatment in women with SU. Englewood, […]
Viveve Medical prices $10m offering
Viveve Medical (NSDQ:VIVE) entered into an underwriting agreement with Ladenburg Thalmann & Co. to price an offering of approximately $10 million. Last month, the company issued and sold 978,202 Class A units of common stock at a public offering price of $1.55 per unit, according to an SEC Form 8-K filing. It also issued nearly […]
Facing delisting, Viveve announces $6.76m funding round
Viveve (NSDQ:VIVE) said last week that it is looking to raise up to $6.76 million in a common stock offering, according to a regulatory filing. The stock is being offered at $0.13 per share, which was the last reported sale price of its common stock on August 15, 2019. The actual number of shares issued […]
Viveve prices $20m offering
Viveve (NSDQ:VIVE) last week priced a follow-on offering worth $20 million. Englewood, Colo.-based Viveve’s eponymous device uses cryogen-cooled monopolar radiofrequency tech designed to treat gynecological conditions. The company said Dec. 6 that it floated 13.3 million shares at $1.50 apiece, for gross proceeds of $20.0 million. The offering includes a 30-day underwriters option on another 2.0 […]
Viveve launches woman-focused stress urinary incontinence device trial
Viveve (NSDQ:VIVE) said on Tuesday it launched a trial exploring the safety and efficacy of its cryogen-cooled monopolar radiofrequency tech designed to treat stress urinary incontinence in women. The new Liberate trial will look to enroll 100 subjects at up to 10 sites in Canada, with patients randomized in a two-to-one ratio for active and sham treatments. […]
Viveve wins FDA nod to continue Viveve II trial
Viveve (NSDQ:VIVE) said yesterday it won FDA clearance to continue enrollment in its Viveve II trial exploring the safety and efficacy of its Viveve system for improving sexual function in women following vaginal childbirth. The approval came based off sufficient evidence to support continued enrollment and a lack of subject protection concerns which would preclude continuation, the […]
Viveve settles IP suit against Thermigen
Viveve (NSDQ:VIVE) said this week it inked a settlement and licensing agreement with Thermigen and associated defendants to resolve a patent litigation claiming Thermigen improperly used Viveve intellectual property with its ThermiVa system. The resolution clears up all pending disputes between the companies, according to an SEC filing from Englewood, Colo.-based Viveve, and grants Thermigen a non-exclusive, […]
Viveve closes $32m offering
Viveve (NSDQ:VIVE) said today it closed a $32.4 million offering with funds slated to support continued research and development and commercialization of its products. The Englewood, Colo.-based company said it sold a total of 11.5 million shares of stock at $3 per share, including shares sold during the full exercise of an underwriters option to purchase […]
